Simple Biomarker Test Could Help Guide Prostate Biopsy Decisions
Prostate cancer risk stratification is challenging in men who have had a previous negative biopsy. The diagnostic value of prostate-specific antigen (PSA) is limited because most men had an initial biopsy because of a PSA elevation. The investigators previously showed that in biopsy-naive men, MyProstateScore (LynxDx) can rule out GG ≥ 2 cancer with a 98% negative predictive value and 97% sensitivity. The new study validates the test's use in men with a previous negative biopsy, adding confidence to the decision of whether to be biopsied again.
@mansoor A MyProstateScore of 15 or below had a 100% negative predictive value and sensitivity for GG ≥ 2 cancer and would have prevented 23% of unnecessary biopsies. A score above 40 had a 19% risk of GG ≥ 2 disease. A score of 15 to 40 had a 6.5% risk of GG ≥ 2 disease. Together, the data suggest that men with a MyProstateScore of 15 or below can "confidently forego biopsy," that most men with scores of 15-40 "are unlikely to benefit from repeat biopsy," and a score greater than 40 "supports proceeding to repeat biopsy."